SLC20A1 and chronic kidney disease: Administration of PPi prevented the CKD-induced upregulation of aortic Pit-1 mRNA, suggesting that PPi, by altering the concentration of phosphate transporter inhibitors (such as, e.g., uremic toxins) [37], either directly or indirectly inhibits expression of this important stimulator of arterial calcification.